Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Minute Insights Ophthalmic Approvals

Minute Insight: iSTAR Medical Receives CE Mark For Glaucoma Device

  • News

Executive Summary

MINIject has been approved in Europe for open-angle glaucoma patients.

You may also be interested in...



Minute Insight: AbbVie Bets Big On Glaucoma Market With iSTAR Purchase Deal

The pharmaceutical company has made a bold play to expand its presence in the device space, giving iSTAR upfront cash in a deal that grants it the right to buy iSTAR for almost half a billion dollars.

The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.

Execs On The Move: April 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

Table

View full table

Topics

Related Companies

Tags:
Minute Insights Ophthalmic Approvals
Latest Headlines

UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit

The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment

EU Regulatory Roundup, May 2023: MDR Extension Updates Resume

See All
UsernamePublicRestriction

Register

MT144731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By